In a front-loaded deal worth up to US$570 M, Medivation has move to expand its oncology franchise with the acquisition of BioMarin Pharmaceutical’s talazoparib (BMN 673), an oral poly(ADP ribose) polymerase (PARP) inhibitor being evaluated in a Phase III clinical trial for the treatment of BRCA-mutated breast cancer. The drug candidate will augment and diversify Medivation’s existing oncology portfolio, which is led by Xtandi® (enzalutamide). The deal marks BioMarin’s departure from oncology R&D, allowing it to focus on its core area of rare diseases.